Gilead Sciences, Inc. (GILD) Stock Analysis and Metrics

Gilead Sciences

NASDAQ: GILD

$134.28 ▼ -2.02 (-1.48%)

At close: Jul 17, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap156.45 Bn

P/E16.36

P/S5.26

Div. Yield0.03

ROIC (Qtr)0.00

Total Debt (Qtr)22.17 Bn

Revenue Growth (1y) (Qtr)4.39

Add ratio to table…

About

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes innovative medicines to treat life threatening diseases including HIV, viral hepatitis, COVID-19, and cancer. The company has pursued breakthroughs in medicine for more than 3 decades with the goal of creating a healthier world for all people. It focuses on virology, oncology, and inflammation and has built a portfolio of more than 25 therapies that are marketed in over 35 countries worldwide. Headquartered in Foster City, California, Gilead is committed to advancing innovative medicines to prevent and treat life threatening diseases. The company employs approximately 17,000 people worldwide and continues to expand its workforce to support research, development, and commercial activities.

Gilead generates revenue primarily from product sales of its antiviral and oncology treatments. Key products include Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza for HIV, Epclusa, Vemlidy, Livdelzi for liver disease, Tecartus, Trodelvy, Yescarta for oncology, and AmBisome and Veklury for other indications. The company also earns royalties from outbound licenses of its intellectual property and receives payments from collaborations with third party partners. Commercial sales are conducted through its own marketing subsidiaries and through wholesalers, distributors, and corporate partners in the United States, Europe, and other regions. In the United States, approximately 90% of gross product sales are made to three large wholesalers: Cardinal Health, Cencora, and McKesson. Gilead operates manufacturing facilities in sites such as Fremont California, La Verne California, Oceanside California, El Segundo California, Santa Monica California, Frederick Maryland, Cork Ireland, Edmonton Canada, and Hoofddorp Netherlands, and relies on contract manufacturing organizations for additional supply. Gilead also generates revenue from licensing agreements that allow other companies to use its patented technologies in exchange for upfront payments, milestones, and ongoing royalties.

Gilead holds a strong position in the HIV treatment market where its single tablet regimens such as Biktarvy and Genvoya are widely prescribed and compete with products from ViiV Healthcare, GSK, and Janssen. In hepatitis C the company’s Epclusa is a leading pan genotypic therapy competing with AbbVie’s Mavyret and Gilead’s earlier products. In oncology its CAR T cell therapies Yescarta and Tecartus compete with Novartis’s Kymriah and Bristol Myers Squib’s Breyanzi. Competitive advantages stem from a robust pipeline, patent protection, first in class mechanisms, and global commercial reach. The company invests heavily in research and development with a focus on discovering new molecules in virology, oncology, and inflammation, and it has advanced numerous product candidates into late stage clinical trials and regulatory review. Its late stage candidates include investigational treatments for HIV prevention, hepatitis delta virus, and various solid tumor indications.

Gilead serves a diverse customer base that includes hospitals, clinics, physicians, and patients who rely on its therapies for chronic and acute conditions. In the United States the majority of product sales are made to three large wholesalers, Cardinal Health, Cencora, and McKesson, which distribute to retail pharmacies and health systems. Internationally the company works with regional distributors, government health agencies, and private insurers to reach end users. Gilead also offers patient support programs that provide counseling, co pay assistance, and navigation services to help individuals access its medicines. The company’s products are used by healthcare providers in more than 35 countries to treat conditions ranging from HIV infection to liver disease and various cancers. These efforts help broaden access to therapies across diverse populations and support adherence to prescribed regimens.

Investment Thesis

▲ Bull case

Gilead Sciences, Inc. is positioned to capture significant long-term growth through its HIV franchise, particularly with the anticipated launch of Biclen in late August 2026 and the ongoing dominance of Biktarvy and Yes2Go. The company highlighted that Biclen addresses a sizable unmet need, as 5% to 6% of people living with HIV are on complex multi-pill regimens, representing a meaningful opportunity to simplify therapy and expand its switch market share. Additionally, Biktarvy maintains over 52% market share in the U.S. and continues to gain share quarter-over-quarter, reflecting sustained physician confidence and product differentiation. The Yes2Go injectable PrEP therapy is already exceeding expectations, with first-quarter sales up 72% sequentially and guidance raised to $1 billion for 2026, driven by strong access (95% coverage with $0 copay) and growing naive user adoption. These factors, combined with no major loss of exclusivity until 2036 and up to seven potential new HIV product launches by 2033, suggest durable, high-margin growth in HIV that the market may be underestimating amid near-term pricing headwinds.
The pending acquisition of Tubulis and the early clinical promise of TUB-40 in platinum-resistant ovarian cancer represent a hidden catalyst that could significantly expand Gilead’s oncology franchise beyond Trodelvy. Management emphasized that Tubulis’ platform offers transformative potential, with TUB-40 showing durable responses in a broad ovarian cancer population without biomarker selection and a favorable toxicity profile lacking lung, ocular, or neuropathic toxicity. The company noted that the ovarian cancer opportunity alone could justify the transaction price, and with plans to enter registrational Phase 3 studies in 2027, TUB-40 has a clear path to becoming a leading ADC in a high-unmet-need indication. Furthermore, the platform’s ALCO-5 and P5 technologies enable novel payload development, creating a sustainable pipeline that leverages Gilead’s medicinal chemistry expertise, which may not yet be fully reflected in investor expectations.
Gilead’s strategic investments in cell therapy and inflammation, particularly through the Arcellx and Oral Medicines acquisitions, are laying the groundwork for multi-year growth that is not yet priced into the stock. The company highlighted that anitocel, with its deep, durable efficacy and differentiated safety profile (no delayed neurotoxicity or enterocolitis), is being evaluated in earlier lines of multiple myeloma, including the Phase 3 IMagine-3 trial with enrollment completing in Q2 2026, and has potential in newly diagnosed disease. Similarly, gamgertamig from Oral Medicines has shown rapid, deep, and sustained B-cell depletion in over 60 patients with immune-mediated diseases, with Orphan Drug and Fast Track designations for AIHA and ITP, and registrational trials targeted as early as 2027. These assets, combined with Kite’s manufacturing and commercialization capabilities, position Gilead to build a foundational presence in autoimmune diseases and cell therapy, with meaningful revenue contributions expected starting in 2027 and beyond, which the market may be overlooking due to near-term EPS dilution from acquisition-related IPR&D charges.

Gilead Sciences, Inc. is positioned to capture significant long-term growth through its HIV franchise, particularly with the anticipated launch of Biclen in late August 2026 and the ongoing dominance of Biktarvy and Yes2Go. The company highlighted that Biclen addresses a sizable unmet need, as 5% to 6% of people living with HIV are on complex multi-pill regimens, representing a meaningful opportunity to simplify therapy and expand its switch market share. Additionally, Biktarvy maintains over 52% market share in the U.S. and continues to gain share quarter-over-quarter, reflecting sustained physician confidence and product differentiation. The Yes2Go injectable PrEP therapy is already exceeding expectations, with first-quarter sales up 72% sequentially and guidance raised to $1 billion for 2026, driven by strong access (95% coverage with $0 copay) and growing naive user adoption. These factors, combined with no major loss of exclusivity until 2036 and up to seven potential new HIV product launches by 2033, suggest durable, high-margin growth in HIV that the market may be underestimating amid near-term pricing headwinds.
The pending acquisition of Tubulis and the early clinical promise of TUB-40 in platinum-resistant ovarian cancer represent a hidden catalyst that could significantly expand Gilead’s oncology franchise beyond Trodelvy. Management emphasized that Tubulis’ platform offers transformative potential, with TUB-40 showing durable responses in a broad ovarian cancer population without biomarker selection and a favorable toxicity profile lacking lung, ocular, or neuropathic toxicity. The company noted that the ovarian cancer opportunity alone could justify the transaction price, and with plans to enter registrational Phase 3 studies in 2027, TUB-40 has a clear path to becoming a leading ADC in a high-unmet-need indication. Furthermore, the platform’s ALCO-5 and P5 technologies enable novel payload development, creating a sustainable pipeline that leverages Gilead’s medicinal chemistry expertise, which may not yet be fully reflected in investor expectations.
Gilead’s strategic investments in cell therapy and inflammation, particularly through the Arcellx and Oral Medicines acquisitions, are laying the groundwork for multi-year growth that is not yet priced into the stock. The company highlighted that anitocel, with its deep, durable efficacy and differentiated safety profile (no delayed neurotoxicity or enterocolitis), is being evaluated in earlier lines of multiple myeloma, including the Phase 3 IMagine-3 trial with enrollment completing in Q2 2026, and has potential in newly diagnosed disease. Similarly, gamgertamig from Oral Medicines has shown rapid, deep, and sustained B-cell depletion in over 60 patients with immune-mediated diseases, with Orphan Drug and Fast Track designations for AIHA and ITP, and registrational trials targeted as early as 2027. These assets, combined with Kite’s manufacturing and commercialization capabilities, position Gilead to build a foundational presence in autoimmune diseases and cell therapy, with meaningful revenue contributions expected starting in 2027 and beyond, which the market may be overlooking due to near-term EPS dilution from acquisition-related IPR&D charges.

▼ Bear case

Gilead Sciences, Inc. faces significant near-term financial headwinds from policy-related changes that could undermine its base business growth expectations, despite the company’s optimism. Management acknowledged a roughly 2% growth headwind from the U.S. government drug pricing agreement and proposed Affordable Care Act changes, which are expected to reduce Medicaid pricing and negatively impact HIV product sales. While the company raised its 2026 HIV sales growth guidance to 8% from 6%, this assumes continued momentum from Biktarvy, Descovy, and Yes2Go, yet the pricing pressure could disproportionately affect lower-income patients and constrain uptake, especially in Medicaid populations. Furthermore, the reliance on seasonal inventory drawdowns to explain sequential sales declines in HIV and other businesses may mask underlying demand weakness, particularly if the policy headwinds are more persistent or severe than anticipated, calling into question the sustainability of the reported growth trajectory.
The oncology franchise, while showing strength in Trodelvy, carries substantial risk from increasing competition and uncertain timelines for pipeline assets, which may limit upside potential. Although Trodelvy received a positive CHMP opinion for first-line metastatic TNBC in Europe and is expected to face FDA decisions in the second half of 2026, competitors like AstraZeneca and Daiichi’s datopotamab deruxtecan are advancing with claims of superior overall survival in immunotherapy-ineligible patients, potentially eroding Trodelvy’s market opportunity. Meanwhile, pipeline assets such as GS-3242 (long-acting HIV treatment) and anitocel face long development horizons, with GS-3242 not expected to launch until 2031–2033 and anitocel revenue not anticipated until early 2027, leaving a gap in near-term catalysts. The company’s emphasis on the ovarian cancer opportunity from Tubulis alone justifying the deal price may also reflect an overreliance on a single early-stage asset, increasing execution risk if TUB-40 fails to demonstrate broader efficacy in platinum-sensitive ovarian cancer or other tumor types.
Gilead’s aggressive M&A strategy, while strategically sound, introduces substantial financial and integration risks that could pressure margins and divert focus from core execution, despite management’s confidence in absorbing incremental costs. The upfront IPR&D investments of approximately $11.5 billion from the Arcellx, Oral Medicines, and Tubulis acquisitions are expected to cause a full-year 2026 non-GAAP loss per share of $1.05 to $0.65, with operating income impacted by nondeductible expenses driving an effective tax rate between 140% and 190%. Although management argues that commercial outperformance offsets these costs on an EPS basis, the sheer scale of these transactions—totaling over $5 billion in upfront payments—raises concerns about integration complexity, particularly across three distinct platforms (cell therapy, ADC, and inflammation) simultaneously. Furthermore, the expectation that R&D expenses will increase a mid-single-digit percentage in 2026, coupled with SG&A absorbing incremental costs, suggests limited near-term margin expansion, and any delays in clinical trial readouts or regulatory approvals could prolong the period of financial drag, undermining the company’s disciplined financial management narrative.

Gilead Sciences, Inc. faces significant near-term financial headwinds from policy-related changes that could undermine its base business growth expectations, despite the company’s optimism. Management acknowledged a roughly 2% growth headwind from the U.S. government drug pricing agreement and proposed Affordable Care Act changes, which are expected to reduce Medicaid pricing and negatively impact HIV product sales. While the company raised its 2026 HIV sales growth guidance to 8% from 6%, this assumes continued momentum from Biktarvy, Descovy, and Yes2Go, yet the pricing pressure could disproportionately affect lower-income patients and constrain uptake, especially in Medicaid populations. Furthermore, the reliance on seasonal inventory drawdowns to explain sequential sales declines in HIV and other businesses may mask underlying demand weakness, particularly if the policy headwinds are more persistent or severe than anticipated, calling into question the sustainability of the reported growth trajectory.
The oncology franchise, while showing strength in Trodelvy, carries substantial risk from increasing competition and uncertain timelines for pipeline assets, which may limit upside potential. Although Trodelvy received a positive CHMP opinion for first-line metastatic TNBC in Europe and is expected to face FDA decisions in the second half of 2026, competitors like AstraZeneca and Daiichi’s datopotamab deruxtecan are advancing with claims of superior overall survival in immunotherapy-ineligible patients, potentially eroding Trodelvy’s market opportunity. Meanwhile, pipeline assets such as GS-3242 (long-acting HIV treatment) and anitocel face long development horizons, with GS-3242 not expected to launch until 2031–2033 and anitocel revenue not anticipated until early 2027, leaving a gap in near-term catalysts. The company’s emphasis on the ovarian cancer opportunity from Tubulis alone justifying the deal price may also reflect an overreliance on a single early-stage asset, increasing execution risk if TUB-40 fails to demonstrate broader efficacy in platinum-sensitive ovarian cancer or other tumor types.
Gilead’s aggressive M&A strategy, while strategically sound, introduces substantial financial and integration risks that could pressure margins and divert focus from core execution, despite management’s confidence in absorbing incremental costs. The upfront IPR&D investments of approximately $11.5 billion from the Arcellx, Oral Medicines, and Tubulis acquisitions are expected to cause a full-year 2026 non-GAAP loss per share of $1.05 to $0.65, with operating income impacted by nondeductible expenses driving an effective tax rate between 140% and 190%. Although management argues that commercial outperformance offsets these costs on an EPS basis, the sheer scale of these transactions—totaling over $5 billion in upfront payments—raises concerns about integration complexity, particularly across three distinct platforms (cell therapy, ADC, and inflammation) simultaneously. Furthermore, the expectation that R&D expenses will increase a mid-single-digit percentage in 2026, coupled with SG&A absorbing incremental costs, suggests limited near-term margin expansion, and any delays in clinical trial readouts or regulatory approvals could prolong the period of financial drag, undermining the company’s disciplined financial management narrative.

Peer Comparison

Companies in the Drug Manufacturers - General

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LLY	ELI LILLY & Co	1,066.16 Bn	42.18	14.76	43.37 Bn
2	JNJ	Johnson & Johnson	611.69 Bn	29.07	6.35	54.99 Bn
3	ABBV	AbbVie Inc.	444.34 Bn	122.04	7.07	64.53 Bn
4	AZN	Astrazeneca Plc	284.94 Bn	23.78	2,793.52	-24.45 Bn
5	MRK	Merck & Co., Inc.	224.23 Bn	25.00	3.41	49.12 Bn
6	AMGN	Amgen Inc	195.12 Bn	25.02	5.24	57.32 Bn
7	GILD	Gilead Sciences, Inc.	156.45 Bn	16.36	5.26	22.17 Bn
8	PFE	Pfizer Inc	136.01 Bn	11,334.57	5.56	64.46 Bn

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2018)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2018)

Peer Comparison

Create an account

Sign In

Reset Password